OMGs:一种支持卵巢肿瘤护理连续体中多学科决策的多智能体系统
OMGs: A multi-agent system supporting MDT decision-making across the ovarian tumour care continuum
AI总结:
OMGs通过多代理系统在卵巢肿瘤护理连续体中实现与专家MDT共识相当的决策性能,提升资源有限环境下的多学科诊疗能力。
摘要:
卵巢肿瘤管理日益依赖多学科肿瘤板(MDT)讨论来应对治疗复杂性和疾病异质性。然而,全球大多数患者缺乏及时专家共识,特别是在资源有限的中心,MDT资源稀缺或不可用。本文提出了OMGs(卵巢肿瘤多学科智能代理系统),一种多代理AI框架,其中专门领域的代理协作讨论,以整合多学科证据并生成MDT风格的推荐,具有透明的推理依据。为系统评估MDT推荐质量,我们开发了SPEAR(安全性、个性化、证据、可操作性、鲁棒性)并验证了OMGs在广泛的临床场景中跨越护理连续体。在多中心重新评估中,OMGs的性能与专家MDT共识相当(4.45±0.30 vs 4.53±0.23),证据分数更高(4.57 vs 3.92)。在前瞻性多中心评估(59名患者)中,OMGs与常规MDT决定高度一致。关键的是,在人与AI的配对研究中,OMGs在证据和鲁棒性方面最显著地增强了临床医生的推荐,这两个维度在多学科专家不可用时最易受损。这些发现表明,多代理讨论系统可以达到专家MDT共识的性能,有潜力在资源有限的环境中扩大专业肿瘤学专家的可及性。
英文摘要:
Ovarian tumour management has increasingly relied on multidisciplinary tumour board (MDT) deliberation to address treatment complexity and disease heterogeneity. However, most patients worldwide lack access to timely expert consensus, particularly in resource-constrained centres where MDT resources are scarce or unavailable. Here we present OMGs (Ovarian tumour Multidisciplinary intelligent aGent System), a multi-agent AI framework where domain-specific agents deliberate collaboratively to integrate multidisciplinary evidence and generate MDT-style recommendations with transparent rationales. To systematically evaluate MDT recommendation quality, we developed SPEAR (Safety, Personalization, Evidence, Actionability, Robustness) and validated OMGs across diverse clinical scenarios spanning the care continuum. In multicentre re-evaluation, OMGs achieved performance comparable to expert MDT consensus ($4.45 \pm 0.30$ versus $4.53 \pm 0.23$), with higher Evidence scores (4.57 versus 3.92). In prospective multicentre evaluation (59 patients), OMGs demonstrated high concordance with routine MDT decisions. Critically, in paired human-AI studies, OMGs most substantially enhanced clinicians' recommendations in Evidence and Robustness, the dimensions most compromised when multidisciplinary expertise is unavailable. These findings suggest that multi-agent deliberative systems can achieve performance comparable to expert MDT consensus, with potential to expand access to specialized oncology expertise in resource-limited settings.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。